Compare TUSK & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TUSK | TTRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.2M | 116.0M |
| IPO Year | 2016 | N/A |
| Metric | TUSK | TTRX |
|---|---|---|
| Price | $2.17 | $3.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 215.1K | 13.3K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $44,292,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.68 | $2.57 |
| 52 Week High | $2.96 | $5.98 |
| Indicator | TUSK | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 44.23 |
| Support Level | $1.72 | $2.64 |
| Resistance Level | $2.25 | $4.01 |
| Average True Range (ATR) | 0.14 | 0.22 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 17.72 | 33.33 |
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes well completion services (Well Completion), infrastructure services (Infrastructure) and natural sand proppant services (Sand). Key revenue is generated from Infrastructure which include electric utility infrastructure services to government-funded utilities, private utilities, public investor-owned utilities, etc.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.